RLAY
What one share of Relay Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Our Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed.
Relay Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$1.57 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.16 |
| Cash and investments | $0.55 |
| Book value | $4.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$21.82 | $2.32 | −$21.49 | — | −$44.69 |
| 2020 | $1.94 | −$5.40 | $0.05 | −$2.45 | — | — |
| 2021 | $0.03 | −$3.82 | $0.04 | −$0.82 | — | $8.30 |
| 2022 | $0.01 | −$2.59 | $0.08 | −$2.13 | — | $7.85 |
| 2023 | $0.21 | −$2.79 | $0.03 | −$2.48 | — | $5.90 |
| 2024 | $0.07 | −$2.36 | $0.01 | −$1.76 | — | $4.64 |
| 2025 | $0.09 | −$1.61 | $0.00 | −$1.37 | — | $3.26 |